Given the results that plerixafor treatment increased the number of peripheral CD4+ and CD8+ T cells during sepsis, we sought to interrogate the immunophenotypic characteristics of these two cell populations to determine the effect of plerixafor administration on co-inhibitory marker expression, specifically the expression of PD-1. The gene discussed is CD4; the disease is Sepsis.